ArticleFrontiers in public health2022
Impact of comorbidity on patients with COVID-19 in India: A nationwide analysis.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Age and comorbidity in COVID-19 mortality: a retrospective cohort study using multivariable regression and interaction analyses.BMC infectious diseases · 2026Article
- Hematological and biochemical markers for predicting severity in COVID-19 patients.BMC infectious diseases · 2026Observational
- Effect of Comorbidities on In-hospital COVID-19 Mortality across Age Groups: A Retrospective Cohort Study in Iran.Medical journal of the Islamic Republic of Iran · 2026Article
- A state wise analysis of the socioeconomic and health impacts of the COVID-19 pandemic in India: lessons for future health system preparedness.Frontiers in public health · 2026Article
- Analyzing COVID-19 progression with Markov multistage models: insights from a Korean cohort.Genomics & informatics · 2025Article
- Fuzzy APPSS: A novel method for quantifying COVID-19 impact in India under triangular spherical fuzzy environment.Scientific reports · 2024Article
- AutoML-Driven Insights into Patient Outcomes and Emergency Care During Romania's First Wave of COVID-19.Bioengineering (Basel, Switzerland) · 2024Article
- Mortality Impact of Severe COVID-19 in the ICU: A Study from the Târgu Mureș Support Unit.Life (Basel, Switzerland) · 2024Article
- Influence of simultaneous comorbidities on COVID-associated acute respiratory distress syndrome mortality in people with diabetes.Journal of Taibah University Medical Sciences · 2024Article
- Epidemiology of COVID-19 mortality in Nepal: An analysis of the National Health Emergency Operation Center data.Public health challenges · 2023Article
- Individual and mutual effects of diabetes, hypertension, and obesity on acute respiratory distress syndrome mortality rates in clinical patients: a multicentre study.Frontiers in public health · 2023Article
- Is Omicron really mild? - Comparative analysis of comorbidities and disease outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants.Indian journal of medical microbiologyObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The emergence of coronavirus disease (COVID-19) as a global pandemic has resulted in the loss of many lives and a significant decline in global economic losses. Thus, for a large country like India, there is a need to comprehend the dynamics of COVID-19 in a clustered way. Objective: To evaluate the clinical characteristics of patients with COVID-19 according to age, gender, and preexisting comorbidity. Patients with COVID-19 were categorized according to comorbidity, and the data over a 2-year period (1 January 2020 to 31 January 2022) were considered to analyze the impact of comorbidity on severe COVID-19 outcomes. Methods: For different age/gender groups, the distribution of COVID-19 positive, hospitalized, and mortality cases was estimated. The impact of comorbidity was assessed by computing incidence rate (IR), odds ratio (OR), and proportion analysis. Results: The results indicated that COVID-19 caused an exponential growth in mortality. In patients over the age of 50, the mortality rate was found to be very high, ~80%. Moreover, based on the estimation of OR, it can be inferred that age and various preexisting comorbidities were found to be predictors of severe COVID-19 outcomes. The strongest risk factors for COVID-19 mortality were preexisting comorbidities like diabetes (OR: 2.39; 95% confidence interval (CI): 2.31-2.47; Conclusion: This study concluded that elderly patients with preexisting comorbidities were at an increased risk of COVID-19 mortality. Patients in the elderly age group with underlying medical conditions are recommended for preventive medical care or medical resources and vaccination against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.